Single vaccine could protect against all coughs, colds and flus
Source: Hacker News
Could a different style of vaccine mark the end of the winter cold?
A single nasal‑spray vaccine could protect against all coughs, colds, flus, bacterial lung infections, and may even ease allergies, say US researchers. The team at Stanford University has tested their “universal vaccine” in animals and still needs to conduct human clinical trials. Their approach marks a “radical departure” from the way vaccines have been designed for more than 200 years.
How the vaccine works
- Delivery: Administered as a nasal spray, the vaccine leaves lung macrophages on “amber alert,” ready to act against any invading pathogen.
- Duration: In animal experiments the heightened state of readiness lasted about three months.
- Efficacy: Researchers observed a 100‑to‑1,000‑fold reduction in viruses crossing the lung barrier. For any that did, the rest of the immune system responded “in warp‑speed time.”
- Broad protection: The vaccine also protected against two bacterial species—Staphylococcus aureus and Acinetobacter baumannii—and appeared to dampen responses to house‑dust‑mite allergens, a common trigger of allergic asthma.
“This vaccine, what we term a universal vaccine, elicits a far broader response that is protective against not just the flu virus, not just the Covid virus, not just the common cold virus, but against virtually all viruses, and as many different bacteria as we’ve tested, and even allergens.” – Prof. Bali Pulendran, Stanford University
Expert commentary
- Prof. Bali Pulendran (Stanford) – Emphasized that the vaccine’s mechanism is a radical departure from traditional vaccine design.
- Prof. Daniela Ferreira (University of Oxford) – Called the research “really exciting” and noted it could change how we protect people from common respiratory infections. She highlighted the study’s clear explanation of the new vaccine style as a major strength.
- Prof. Jonathan Ball (Liverpool School of Tropical Medicine) – While praising the work as “exciting,” he warned that keeping the immune system on high alert could risk unintended side effects (“friendly fire”).
Potential challenges
- Human translation: It is unknown whether the same “amber‑alert” effect can be achieved in people or how long it would last. Differences between mouse and human immune systems, shaped by decades of infections, may affect outcomes.
- Delivery method: The nasal spray used in animals might need to be delivered via a nebuliser to reach deeper human lung tissue.
- Safety concerns: Over‑activating the immune system could lead to immune disorders or other side effects. Researchers stress that the vaccine should complement—not replace—existing vaccines.
- Trial design: Planned human studies involve vaccinating participants and then deliberately exposing them to pathogens to assess protection, raising ethical and safety considerations.
Future directions
- Pandemic response: In early stages of a pandemic (e.g., early 2020 Covid), a universal vaccine could buy time while pathogen‑specific vaccines are developed, potentially reducing mortality and disease severity.
- Seasonal use: A seasonal spray administered at the start of winter could imprint broad immunity against the array of respiratory bugs that typically circulate.
Correction (19 February): An earlier version incorrectly referred to Edward Jenner as “Sir.” He was never knighted.